The clinical-stage biotechnology company, focused on the development of novel medicines that can prevent life-threatening infections, said results of the trial are expected in the first quarter of this year.
XF-73 is a first-in-class drug candidate from Destiny Pharma's XF platform, initially being developed for the prevention of post-surgical staphylococcal infections, such as methicillin-resistant Staphylococcus aureus (MRSA), which cause significant complications and increased healthcare costs in the hospital setting.
It has been awarded both qualifying infectious disease product (QIDP) and Fast Track status by the US Food and Drug Administration.
Neil Clark, the chief executive of Destiny Pharma, said the company was pleased to have completed the enrollment and is looking forward to announcing the full results of the study and moving on to planning the Phase 3 clinical programme.
“There is a global need for better treatments to prevent post-surgical infections in hospitals as recognised in the FastTrack status awarded to XF-73 by the US FDA. There is also a significant commercial opportunity for XF-73 in the hospital setting which we estimate could generate peak annual product sales of US$1 billion in the US alone,” Clark said in a statement.
“2020 was a transformational year for Destiny Pharma as we accelerated our strategy to build a world-leading anti-infection company with a robust pipeline. We established a biotherapeutic/microbiome pipeline alongside our existing XF platform and are now co-developing SPOR-COV as a novel, preventive treatment for COVID-19,” he continued.
“We also raised £10.4 million to acquire NTCD-M3, a Phase 3 ready biotherapeutic treatment for the prevention of C. difficile infection recurrence,” Clark added.